Recipharm, a contract development and manufacturing organization (CDMO), has signed a letter of intent with Moderna, a U.S.-based biotech, to formulate, fill and finish mRNA-1273, Moderna’s COVID-19 vaccine candidate. The activity will be performed in Recipharm’s drug product manufacturing facility located in Monts, France. Recipharm has reserved capacity to support the anticipated demand for the vaccine and is already in the process of recruiting additional staff and making certain investments ...